This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Melero I, Ochoa MC, Molina C, Sanchez-Gregorio S, Garasa S, Luri-Rey C, et al. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies. EMBO Mol Med. 2023;15:e17804.
van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell. 2018;175:1744–55.e15.
André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731–43.e13.
Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, et al. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:3383–93.
Cascone T, Kar G, Spicer JD, García-Campelo R, Weder W, Daniel DB, et al. Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial. Cancer Discov. 2023;13:2394–411.
Minute L, Teijeira A, Sanchez-Paulete AR, Ochoa MC, Alvarez M, Otano I, et al. Cellular cytotoxicity is a form of immunogenic cell death. J Immunother Cancer. 2020;8:e000325.
Patel SP, Alonso-Gordoa T, Banerjee S, Wang D, Naidoo J, Standifer NE, et al. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. J Immunother Cancer. 2024;12:e007340.
Acknowledgements
This work was supported by the PID2020-112892RB-100 funded by MCIN/ AEI/10.13039/501100011033, PDC2021-121769-C21 grant funded by MCIN/ AEI/10.13039/501100011033 and The European Union Next GenerationEU/ PRTR, the Fundación La Caixa (HR21-0083), the AACR-AstraZeneca career development award for physician-scientist in honor of Jose Baselga, Partners of Choice Network AstraZeneca (AZ PoC) and the Fundació La Marató TV3 (488/C/2019) and Fundación FERO. MA was supported by a Spanish Association Against Cancer’s Investigator grant (INVES19041ALVA) and currently receives “Ayudas Ramon y Cajal” (RYC2021-033381) from the MCIN/ AEI/10.13039/501100011033. IM, CE, and MA are part of to the Spanish Cancer Immunotherapy Network REINCA (RED2022-134831-T).
Author information
Authors and Affiliations
Contributions
IM and MA wrote the manuscript. CM and CE assisted with the preparation of the manuscript. All authors have read and agreed to the published version of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
CM and CE declare no competing interests. IM reports receiving commercial research grants from AstraZeneca, BMS, Highlight Therapeutics, Alligator, Pfizer Genmab and Roche; has received speakers bureau honoraria from MSD; and is a consultant or advisory board member for BMS, Roche, AstraZeneca, Genmab, Pharmamar, F-Star, Bioncotech, Bayer, Numab, Pieris, Gossamer, Alligator and Merck Serono. MA reports receiving commercial research grants from Highlight Therapeutics and Pharmamar.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Melero, I., Molina, C., Eguizabal, C. et al. Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer. Genes Immun (2024). https://doi.org/10.1038/s41435-024-00267-6
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41435-024-00267-6